EuropaBio

21/12/2022

🟣 With the right policies and incentives in place, has the possibility to capitalise on the resources of twenty-seven Member States and break the barriers to growth for established , , and developing orphan medicinal products ( ).

🟣 The revision of the is an opportunity to build on past successes and enable Europe to become a leading region for innovation in the decades to come.

🟣 Read the blog post by Dr. Claire Skentelbery: 👉 https://bit.ly/3Eotcvb.

🟣

Europe’s complex rare disease ecosystem relies primarily on a fragile complementary relationship between academia, start-ups, and well-established companies to bring scientific and technological progress. The recent publication of draft impact assessment by Politico Europe renewed concerns that th...

20/12/2022

🟣 The has already delivered for but more can be done. 👇

🟣

📌

19/12/2022

🟣 The European Union continues to grow as a region of healthcare excellence.

🟣 Creating an environment to attract, maintain, and increase investments in innovative biotech discoveries will ensure that the EU is the world’s most advanced region for both public and private biotech and .

🟣 EuropaBio’s vision: a Europe where delivers benefits across society, from high-skill jobs and economic strength to ground-breaking treatments that change and save lives.

🟣 Watch the video to learn more! 👇



📌

This is "Europabio - Healthcare Biotech (Subtitled)" by Cartoonbase on Vimeo, the home for high quality videos and the people who love them.

16/12/2022

🟣 To support the uptake of , EuropaBio proposes a set of 12 policy and associated , including 3 propositions related to and . 👇

🟣

📌 https://bit.ly/3Po2JS8

15/12/2022

🎤 We sat down with our new member SenseUP Biotechnology, to find out more about the natural evolution approach for novel and products. 🔎

📰 Read the interview with Dr. Georg Schaumann, CEO and Founder: 👉 https://bit.ly/3WfNjl2.

15/12/2022

🟣 Increased access to genetic testing is a significant opportunity for and systems in by supporting the deployment of targeted therapeutic strategies.

🟣 But investments in are essential to make testing more widely available to support the broader needs of the population.

🟣 To support the uptake of , EuropaBio proposes a set of 12 policy and associated , including 3 propositions concerning and . 👇

🟣

📌 https://bit.ly/3Po2JS8

14/12/2022

📢 We are pleased to announce that the German natural evolution company has joined as an associate member! 🤝

🧬 After starting as a spin-off from the Institute for at Forschungszentrum Jülich and undertaking years of systematic technology development, is now working with global players from the , and industries to develop superior production processes. ⚙️

📌 Read the press release: 👉

Brussels, 13 December 2022 – EuropaBio is pleased to announce that the German natural evolution company SenseUp has joined as an associate member.

14/12/2022

🟣 and (non-genetic) tests for genetic risk factors are medical tests used to identify in genes that correlate to a ’s risk of developing a certain .

🟣 Increased access to genetic testing is a significant opportunity for and systems in by supporting the deployment of targeted therapeutic strategies.

🟣 To support the uptake of , EuropaBio proposes a set of 12 policy and associated , including 3 propositions concerning and . 👇

🟣

📌 https://bit.ly/3Po2JS8

13/12/2022

🟣 Advances in science and technology have greatly improved our understanding of the genetic basis of , which have made it possible to redefine many diseases at higher resolution and target them with more precise such as cell and .

🟣 Increased access to genetic testing is a significant opportunity for and systems in by supporting the deployment of targeted therapeutic strategies.

🟣 To support the uptake of , EuropaBio proposes a set of 12 policy and associated . Here are the first 3, about pathways. 👇

🟣

📌 https://bit.ly/3Po2JS8

08/12/2022

🟣 development advances alone do not deliver products to patients. The development pathway requires diverse skills to enable to succeed in delivering treatment solutions.

🟣 One of the most significant bottlenecks for SME and technology maturation is access to professional . This experience gap can only be addressed in the short term by greater public and private with practices and information sharing

🟣 Read our recommendations in the Report: 👉 https://bit.ly/3F4RitS, and register to our Webinar, next week: 👉 https://bit.ly/3haNyiq.

🟣

07/12/2022

🟣 For European ’ growth and survival, it is fundamental to achieve more regulatory across Europe to ensure that find their market with appropriate pricing and reimbursement decisions and that are available to .

🟣 Read our recommendations in the Report: 👉 https://bit.ly/3F4RitS, and register to our Webinar, next week: 👉 https://bit.ly/3haNyiq.

🟣

06/12/2022

🟣 The development field is recent and fast-evolving. While technology progresses rapidly, national regulators must learn and adapt quickly to support the development and approval of new cell and .

🟣 The European Medicines Agency (EMA) and the EU regulatory network have to deliver a streamlined, flexible and coherent regulatory system, with good coordination between the and the Member States, optimising support for new advances in innovation and accelerating .

🟣 Read our recommendations in the Report: 👉 https://bit.ly/3F4RitS, and register to our Webinar, next week: 👉 https://bit.ly/3haNyiq.

🟣